In 2022 Japanese adults aged ≥50 randomised to combined flu/COVID-19 mRNA-1083 or a licensed flu HA vaccine plus mRNA-1273, mRNA-1083 gave non-inferior Day 29 immune responses for all flu strains and SARS-CoV-2, with no serious vaccine-related harms.
RCTn = 2,022
Kostanyan et al. Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan